glp 1 agonist bone density Frontiers GLP-1 Use Associated with Lower

For instance, SAR441255designed with balanced activity across all three receptorsshowed some promising early efficacy for glycaemic control in a phase 1 single-dose study and was generally well tolerated [65], however, no further trials have been reported since 2019

Semaglutide , taken weekly: Possibly the most well-known of them all, FDA-approved under the brand names Ozempic for type 2 diabetes and to reduce the risk of a major adverse cardiovascular event in adults with type 2 diabetes or an established cardiovascular disease and Wegovy for obesity

As of now, GLP-1-related triple agonists are primarily still in the development stage and have not been widely approved for use

Obes Surg (2008) 18(9):11837